JP2009091262A - Calcium antagonist - Google Patents
Calcium antagonist Download PDFInfo
- Publication number
- JP2009091262A JP2009091262A JP2007260673A JP2007260673A JP2009091262A JP 2009091262 A JP2009091262 A JP 2009091262A JP 2007260673 A JP2007260673 A JP 2007260673A JP 2007260673 A JP2007260673 A JP 2007260673A JP 2009091262 A JP2009091262 A JP 2009091262A
- Authority
- JP
- Japan
- Prior art keywords
- calcium
- calcium antagonist
- active ingredient
- carbon atoms
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940127291 Calcium channel antagonist Drugs 0.000 title claims abstract description 59
- 239000000480 calcium channel blocker Substances 0.000 title claims abstract description 52
- 150000001875 compounds Chemical class 0.000 claims abstract description 25
- 239000004480 active ingredient Substances 0.000 claims abstract description 13
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 8
- 125000001118 alkylidene group Chemical group 0.000 claims abstract description 7
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 15
- 239000003795 chemical substances by application Substances 0.000 claims description 15
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 7
- 239000011575 calcium Substances 0.000 claims description 7
- 229910052791 calcium Inorganic materials 0.000 claims description 7
- HBEDSQVIWPRPAY-UHFFFAOYSA-N 2,3-dihydrobenzofuran Chemical compound C1=CC=C2OCCC2=C1 HBEDSQVIWPRPAY-UHFFFAOYSA-N 0.000 claims description 6
- 230000003834 intracellular effect Effects 0.000 claims description 6
- NEDIAPMWNCQWNW-UHFFFAOYSA-N massoia lactone Chemical compound CCCCCC1CC=CC(=O)O1 NEDIAPMWNCQWNW-UHFFFAOYSA-N 0.000 claims description 6
- 230000005764 inhibitory process Effects 0.000 claims description 5
- 208000001286 intracranial vasospasm Diseases 0.000 claims description 4
- 239000001562 (3E)-3-propylidene-2-benzofuran-1-one Substances 0.000 claims description 3
- NGSZDVVHIGAMOJ-YHYXMXQVSA-N (3z)-3-propylidene-2-benzofuran-1-one Chemical compound C1=CC=C2C(=C/CC)/OC(=O)C2=C1 NGSZDVVHIGAMOJ-YHYXMXQVSA-N 0.000 claims description 3
- WMBOCUXXNSOQHM-FLIBITNWSA-N (Z)-3-butylidenephthalide Chemical compound C1=CC=C2C(=C/CCC)/OC(=O)C2=C1 WMBOCUXXNSOQHM-FLIBITNWSA-N 0.000 claims description 3
- WMBOCUXXNSOQHM-DHZHZOJOSA-N 3-Butylidenephthalide Natural products C1=CC=C2C(=C/CCC)\OC(=O)C2=C1 WMBOCUXXNSOQHM-DHZHZOJOSA-N 0.000 claims description 3
- BUNGCZLFHHXKBX-UHFFFAOYSA-N 8-methoxypsoralen Natural products C1=CC(=O)OC2=C1C=C1CCOC1=C2OC BUNGCZLFHHXKBX-UHFFFAOYSA-N 0.000 claims description 3
- QXKHYNVANLEOEG-UHFFFAOYSA-N Methoxsalen Chemical compound C1=CC(=O)OC2=C1C=C1C=COC1=C2OC QXKHYNVANLEOEG-UHFFFAOYSA-N 0.000 claims description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 3
- 125000004122 cyclic group Chemical group 0.000 claims description 3
- 229960004469 methoxsalen Drugs 0.000 claims description 3
- SQBBOVROCFXYBN-UHFFFAOYSA-N methoxypsoralen Natural products C1=C2OC(=O)C(OC)=CC2=CC2=C1OC=C2 SQBBOVROCFXYBN-UHFFFAOYSA-N 0.000 claims description 3
- WMBOCUXXNSOQHM-UHFFFAOYSA-N n-butylidenephthalide Natural products C1=CC=C2C(=CCCC)OC(=O)C2=C1 WMBOCUXXNSOQHM-UHFFFAOYSA-N 0.000 claims description 3
- 239000001301 oxygen Substances 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- DKHZWQLGZWVFFH-SECBINFHSA-N (2r)-2-hexyl-2h-furan-5-one Chemical group CCCCCC[C@H]1OC(=O)C=C1 DKHZWQLGZWVFFH-SECBINFHSA-N 0.000 claims description 2
- MTQPZHNZYWAXEH-UHFFFAOYSA-N 3,4-dimethyl-5-pentylidenefuran-2-one Chemical compound CCCCC=C1OC(=O)C(C)=C1C MTQPZHNZYWAXEH-UHFFFAOYSA-N 0.000 claims description 2
- 102000013830 Calcium-Sensing Receptors Human genes 0.000 claims description 2
- 108010050543 Calcium-Sensing Receptors Proteins 0.000 claims description 2
- 208000005392 Spasm Diseases 0.000 claims description 2
- 206010047139 Vasoconstriction Diseases 0.000 claims description 2
- 239000003416 antiarrhythmic agent Substances 0.000 claims description 2
- 210000003205 muscle Anatomy 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 230000025033 vasoconstriction Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- CJAONIOAQZUHPN-KKLWWLSJSA-N ethyl 12-[[2-[(2r,3r)-3-[2-[(12-ethoxy-12-oxododecyl)-methylamino]-2-oxoethoxy]butan-2-yl]oxyacetyl]-methylamino]dodecanoate Chemical compound CCOC(=O)CCCCCCCCCCCN(C)C(=O)CO[C@H](C)[C@@H](C)OCC(=O)N(C)CCCCCCCCCCCC(=O)OCC CJAONIOAQZUHPN-KKLWWLSJSA-N 0.000 description 13
- 238000002156 mixing Methods 0.000 description 12
- 239000003205 fragrance Substances 0.000 description 11
- 235000013305 food Nutrition 0.000 description 10
- 239000000126 substance Substances 0.000 description 9
- 239000003710 calcium ionophore Substances 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 230000002776 aggregation Effects 0.000 description 7
- 235000009508 confectionery Nutrition 0.000 description 7
- 239000002537 cosmetic Substances 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- -1 phenol compound Chemical class 0.000 description 7
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 238000004220 aggregation Methods 0.000 description 6
- 229910001424 calcium ion Inorganic materials 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 235000000346 sugar Nutrition 0.000 description 6
- 239000003995 emulsifying agent Substances 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000003381 stabilizer Substances 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 206010050661 Platelet aggregation inhibition Diseases 0.000 description 3
- 244000299461 Theobroma cacao Species 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 229960004676 antithrombotic agent Drugs 0.000 description 3
- 206010003119 arrhythmia Diseases 0.000 description 3
- 230000006793 arrhythmia Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000003599 detergent Substances 0.000 description 3
- 239000002270 dispersing agent Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 101000783577 Dendroaspis angusticeps Thrombostatin Proteins 0.000 description 2
- 101000783578 Dendroaspis jamesoni kaimosae Dendroaspin Proteins 0.000 description 2
- 206010047163 Vasospasm Diseases 0.000 description 2
- 229940127218 antiplatelet drug Drugs 0.000 description 2
- 239000003788 bath preparation Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000002213 calciumantagonistic effect Effects 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- 235000014510 cooky Nutrition 0.000 description 2
- 239000008157 edible vegetable oil Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 235000013861 fat-free Nutrition 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 235000011194 food seasoning agent Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 2
- 239000002453 shampoo Substances 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- PJVXUVWGSCCGHT-ZPYZYFCMSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;(3s,4r,5r)-1,3,4,5,6-pentahydroxyhexan-2-one Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO PJVXUVWGSCCGHT-ZPYZYFCMSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- UYNVMODNBIQBMV-UHFFFAOYSA-N 4-[1-hydroxy-2-[4-(phenylmethyl)-1-piperidinyl]propyl]phenol Chemical compound C1CC(CC=2C=CC=CC=2)CCN1C(C)C(O)C1=CC=C(O)C=C1 UYNVMODNBIQBMV-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- ICHISWQVYXYNPA-UHFFFAOYSA-N 5-pentylidenefuran-2-one Chemical compound CCCCC=C1OC(=O)C=C1 ICHISWQVYXYNPA-UHFFFAOYSA-N 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
- 206010059109 Cerebral vasoconstriction Diseases 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010023230 Joint stiffness Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 241000237536 Mytilus edulis Species 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 229940124532 absorption promoter Drugs 0.000 description 1
- 235000010358 acesulfame potassium Nutrition 0.000 description 1
- 229960004998 acesulfame potassium Drugs 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 229940124575 antispasmodic agent Drugs 0.000 description 1
- 235000021425 apple cider vinegar Nutrition 0.000 description 1
- 229940088447 apple cider vinegar Drugs 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 235000020186 condensed milk Nutrition 0.000 description 1
- 229940124558 contraceptive agent Drugs 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000013611 frozen food Nutrition 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000000118 hair dye Substances 0.000 description 1
- 239000003676 hair preparation Substances 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000008099 melanin synthesis Effects 0.000 description 1
- 235000020124 milk-based beverage Nutrition 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 235000020638 mussel Nutrition 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 210000004623 platelet-rich plasma Anatomy 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000033904 relaxation of vascular smooth muscle Effects 0.000 description 1
- 239000008257 shaving cream Substances 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229940034610 toothpaste Drugs 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000002883 vasorelaxation effect Effects 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 235000020985 whole grains Nutrition 0.000 description 1
- 235000008939 whole milk Nutrition 0.000 description 1
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Non-Alcoholic Beverages (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
本発明は、カルシウム拮抗剤に関するものである。さらには、本発明は、カルシウムイオンが関与する不整脈、血管収縮および脳血管攣縮などの改善剤に関与するものである。 The present invention relates to a calcium antagonist. Furthermore, the present invention relates to an improving agent such as arrhythmia, vasoconstriction and cerebral vasospasm involving calcium ions.
カルシウムは、生体の筋収縮や細胞運動などを調節する重要な因子であることが知られている。カルシウム拮抗剤は、細胞外からのカルシウムの流入を抑制し、血管平滑筋などの弛緩を引き起こすことで血流改善や血圧上昇改善に働く。よってカルシウム拮抗剤は、治療薬として高血圧、狭心症、不整脈および脳循環障害などに用いられている。 Calcium is known to be an important factor that regulates muscle contraction and cell movement in the living body. Calcium antagonists act to improve blood flow and blood pressure by suppressing the inflow of calcium from the outside of the cell and causing relaxation of vascular smooth muscle and the like. Therefore, calcium antagonists are used as therapeutic agents for hypertension, angina pectoris, arrhythmias, cerebral circulation disorders, and the like.
たとえば、特許文献１には、カルシウム拮抗効果を併有する血小板凝集抑制剤が提示されている。また、特許文献２には、生薬ケイガイの花穂に含まれるフェノール化合物からなるカルシウム拮抗剤が示されている。特許文献３には、２−（４−ベンジルピペリジノ）−１−（４−ヒドロキシフェニル）プロパノールまたはその塩を有効成分とするカルシウム拮抗剤が提示されている。 For example, Patent Document 1 proposes a platelet aggregation inhibitor having a calcium antagonistic effect. Patent Document 2 discloses a calcium antagonist composed of a phenol compound contained in a herb of a herbal medicine mussel. Patent Document 3 proposes a calcium antagonist containing 2- (4-benzylpiperidino) -1- (4-hydroxyphenyl) propanol or a salt thereof as an active ingredient.
近年では、高齢化社会において使用経験も豊富で安価で提供できる、未病段階から、予防的に各種飲食品や医薬部外品などとして効果を享受できるカルシウム拮抗剤が望まれている。
生体内で起こる多くの反応は、カルシウムイオンによる制御を受けている。本発明者は、これらの生体内カルシウムイオンが原因で引き起こされる様々な生体への悪影響の症状を軽減し、もしくは予防することができる、新規なカルシウム拮抗剤を提供すること、特に、より簡便に入手できるとともに、大量生産が容易に実現可能なカルシウム拮抗剤を提供することを目的とするものである。 Many reactions that occur in vivo are controlled by calcium ions. The inventor of the present invention provides a novel calcium antagonist capable of reducing or preventing various symptoms of adverse effects on living organisms caused by these in vivo calcium ions. An object of the present invention is to provide a calcium antagonist that can be obtained and can be easily mass-produced.
本発明のカルシウム拮抗剤は、下記式（１）乃至（５） The calcium antagonist of the present invention has the following formulas (1) to (5).
（式中、Ｒ１は炭素数１から１０のアルキル基を表し、Ｒ２は炭素数１から１０のアルキリデン基を表し、Ｒ３は炭素数１から３のアルコキシ基を表し、Ｒ４およびＲ５はそれぞれ独立に炭素数１から３の直鎖のアルキル基を表し、Ｒ６は炭素数１から１０の直鎖のアルキリデン基を表す。）で示される含酸素環状構造を有する化合物群から選ばれた少なくとも１種の化合物を有効成分として含有するカルシウム拮抗剤である。 (Wherein R1 represents an alkyl group having 1 to 10 carbon atoms, R2 represents an alkylidene group having 1 to 10 carbon atoms, R3 represents an alkoxy group having 1 to 3 carbon atoms, and R4 and R5 are each independently A straight-chain alkyl group having 1 to 3 carbon atoms, and R6 represents a straight-chain alkylidene group having 1 to 10 carbon atoms.) At least one selected from the group of compounds having an oxygen-containing cyclic structure It is a calcium antagonist containing a compound as an active ingredient.
また、本発明のカルシウム拮抗剤は、２−デセノ−δ−ラクトン、３−プロピリデンフタリド、３−ブチリデンフタリド、２，３−ジヒドロベンゾフラン、８−メトキシソラレンおよび３，４−ジメチル−５−ペンチリデン−５Ｈ−フラン−２−オンからなる群から選ばれた少なくとも１つの化合物を有効成分として含有するカルシウム拮抗剤である。 The calcium antagonist of the present invention includes 2-deceno-δ-lactone, 3-propylidenephthalide, 3-butylidenephthalide, 2,3-dihydrobenzofuran, 8-methoxypsoralen and 3,4-dimethyl-5. -A calcium antagonist containing as an active ingredient at least one compound selected from the group consisting of pentylidene-5H-furan-2-one.
本発明のカルシウム拮抗剤の好ましい態様によれば、前記の２−デセノ−δ−ラクトンは、（Ｒ）−２−デセノ−δ−ラクトンである。 According to a preferred embodiment of the calcium antagonist of the present invention, the 2-deceno-δ-lactone is (R) -2-deceno-δ-lactone.
また、本発明においては前記のカルシウム拮抗剤を用い、カルシウム拮抗剤を有効成分とする抗血栓剤、抗不整脈剤、血管弛緩剤などの血管収縮改善剤、抗脳血管攣縮剤および皮膚および筋肉に対する抗攣縮剤などとすることができる。 In the present invention, the calcium antagonist is used, and an antithrombotic agent, an antiarrhythmic agent, a vasorelaxant and the like, an anticerebral vasospasm agent and an anti-cerebral vasospasm agent and skin and muscle containing the calcium antagonist as an active ingredient It can be used as an antispasmodic agent.
さらに、本発明においては、前記の前記のカルシウム拮抗剤を用い、カルシウム拮抗剤を有効成分として含有する、細胞内遊離カルシウム阻害および／または細胞内カルシウム受容体阻害および／または細胞内カルシウム関連蛋白質阻害を主たる目的とする医薬品とすることができる。 Furthermore, in the present invention, intracellular free calcium inhibition and / or intracellular calcium receptor inhibition and / or intracellular calcium-related protein inhibition, comprising the calcium antagonist described above and containing the calcium antagonist as an active ingredient. Can be used as a main drug.
本発明のカルシウム拮抗剤によれば、カルシウムイオンが係わる不整脈の改善、血管弛緩に伴う狭心症の軽減、および脳血管の攣縮予防や筋肉攣縮による関節硬直などの緩和効果を得ることができる。 According to the calcium antagonist of the present invention, arrhythmia related to calcium ions can be improved, angina pectoris associated with vascular relaxation, and relaxation effects such as prevention of cerebrovascular spasm and joint stiffness due to muscle spasm.
また、本発明のカルシウム拮抗剤は、香料として使用実績がある化合物であり、刺激性などは極めて小さく、飲食品や香粧品類、医薬品など幅広く添加することができる。また、本発明の化合物群は、容易に合成ができるため大量生産が可能である。 Moreover, the calcium antagonist of the present invention is a compound that has been used as a fragrance and has very little irritation and can be widely added to foods, cosmetics, pharmaceuticals, and the like. Further, the compound group of the present invention can be synthesized easily and can be mass-produced.
本発明の、下記式（１）乃至（５） The following formulas (1) to (5) of the present invention
（式中、Ｒ１は炭素数１から１０のアルキル基を表し、Ｒ２は炭素数１から１０のアルキリデン基を表し、Ｒ３は炭素数１から３のアルコキシ基を表し、Ｒ４およびＲ５はそれぞれ独立に炭素数１から３の直鎖のアルキル基を表し、Ｒ６は炭素数１から１０の直鎖のアルキリデン基を表す）で示される含酸素環状構造を有する化合物は、いずれも公知の方法によって製造することができる。 (Wherein R1 represents an alkyl group having 1 to 10 carbon atoms, R2 represents an alkylidene group having 1 to 10 carbon atoms, R3 represents an alkoxy group having 1 to 3 carbon atoms, and R4 and R5 are each independently Any of the compounds having an oxygen-containing cyclic structure represented by a straight-chain alkyl group having 1 to 3 carbon atoms and R6 represents a straight-chain alkylidene group having 1 to 10 carbon atoms is produced by a known method. be able to.
これらの化合物群の内、上記式（１）の化合物としては、２−デセノ−δ−ラクトンが一般に市販されており、入手が容易であることから特に好ましく用いられる。また、上記式（２）の化合物については、３−プロピリデンフタリドと３−ブチリデンフタリドが一般に市販されており、入手が容易であることから特に好ましく用いられる。また、上記式（３）の化合物としては、８−メトキシソラレンが一般に市販されており、入手が容易であることから特に好ましく用いられる。上記式（４）の化合物としては、２，３−ジヒドロベンゾフランが一般に市販されており、入手が容易であることから特に好ましく用いられる。また、上記式（５）の化合物としては、３，４−ジメチル−５−ペンチリデン−５Ｈ−フラン−２−オン（以下、ボボリドという。）が、公知の方法で簡便に製造することができるため好ましく用いられる。上記式（５）の化合物の製造方法としては具体的には、ドイツ特許１０７２６２９号公報および米国特許３２５１３６６号明細書に記載の方法や、Ｊ．Ａｍ．Ｃｈｅｍ．Ｓｏｃ． １９８６，１０８，５２０−５２２に記載の方法が挙げられる。 Among these compound groups, as the compound of the above formula (1), 2-deceno-δ-lactone is generally commercially available and is particularly preferably used because it is easily available. Moreover, about the compound of the said Formula (2), 3-propylidene phthalide and 3-butylidene phthalide are generally marketed, and since it is easy to acquire, they are used especially preferable. Moreover, as a compound of the said Formula (3), 8-methoxy psoralen is generally marketed and it is especially preferable since it is easy to acquire. As the compound of the above formula (4), 2,3-dihydrobenzofuran is generally commercially available and is particularly preferably used because it is easily available. As the compound of the above formula (5), 3,4-dimethyl-5-pentylidene-5H-furan-2-one (hereinafter referred to as bobolido) can be easily produced by a known method. Preferably used. Specific examples of the method for producing the compound of the above formula (5) include the method described in German Patent No. 1072629 and US Pat. No. 3,251,366, J. Pat. Am. Chem. Soc. 1986, 108, 520-522.
さらに、本発明のカルシウム拮抗剤のうち、２−デセノ−δ−ラクトンはラセミ体を用いてもよいが、（Ｒ）−体の方が活性が強いため（Ｒ）−体を用いることがより好ましい。 Furthermore, among the calcium antagonists of the present invention, racemic isomers may be used for 2-deceno-δ-lactone, but the (R) -isomer is more preferable because the (R) -isomer is more active. preferable.
本発明のカルシウム拮抗剤は、用途に応じて、エタノール、水、プロピレングリコール、グリセリン、食用油脂またはそれらの混合溶液などの溶剤、医薬や食品に適用可能な塩類、糖、糖アルコール、賦形剤、可溶化剤、乳化剤、分散剤、安定化剤、抗酸化剤、色素および香料などを適宜配合することができる。 The calcium antagonist of the present invention is a solvent such as ethanol, water, propylene glycol, glycerin, edible oil or fat, or a mixed solution thereof, salts applicable to pharmaceuticals and foods, sugars, sugar alcohols, excipients, depending on applications. , Solubilizers, emulsifiers, dispersants, stabilizers, antioxidants, pigments, fragrances and the like can be appropriately blended.
本発明のカルシウム拮抗剤において、前記の式（１）〜式（５）の化合物群の含有量は単独の化合物もしくは複数化合物を組み合わせた組成物で、０．０００１〜１００質量％であることが好ましい。 In the calcium antagonist of the present invention, the content of the compound group of the above formulas (1) to (5) is a single compound or a composition combining a plurality of compounds, and is 0.0001 to 100% by mass. preferable.
本発明のカルシウム拮抗剤の形態は、特に限定されない。例えば、液状のままでもよく、公知の方法によって乳化、分散および粉末化するなど、形態は用途に応じて適宜選択することができる。 The form of the calcium antagonist of the present invention is not particularly limited. For example, it may be in a liquid state, and the form can be appropriately selected depending on the application, such as emulsification, dispersion and pulverization by a known method.
本発明のカルシウム拮抗剤は、ビタミン、ミネラルおよびアミノ酸などの栄養強化剤、抗酸化剤、抗菌剤およびその他の薬剤などと配合して使用することができる。また、本発明のカルシウム拮抗剤は、他のカルシウム拮抗剤と併用してもよい。 The calcium antagonist of the present invention can be used in combination with a nutrient enhancer such as vitamins, minerals and amino acids, antioxidants, antibacterial agents and other agents. The calcium antagonist of the present invention may be used in combination with other calcium antagonists.
本発明のカルシウム拮抗剤を、医薬品もしくは医薬部外品として製剤化する場合は、必要に応じて安定化剤、着色剤、嬌味剤、香料、賦形剤、溶剤、界面活性剤、乳化剤、保存剤、溶解補助剤、等張化剤、緩衝剤、保湿剤、結合剤、被覆剤、潤沢剤、崩壊剤、経皮吸収剤などを加え、液剤、粉剤、散剤、顆粒剤、錠剤、糖衣剤、カプセル剤、懸濁剤、座剤、浴剤、軟膏、クリーム、ゲル、貼付剤、注射液および点眼剤など任意の剤形を選択することができる。 When formulating the calcium antagonist of the present invention as a pharmaceutical product or quasi-drug, a stabilizer, a coloring agent, a flavoring agent, a fragrance, an excipient, a solvent, a surfactant, an emulsifier, Add preservatives, solubilizers, tonicity agents, buffers, humectants, binders, coatings, lubricants, disintegrants, transdermal agents, etc., liquids, powders, powders, granules, tablets, sugar coatings Arbitrary dosage forms such as agents, capsules, suspensions, suppositories, bath preparations, ointments, creams, gels, patches, injection solutions and eye drops can be selected.
本発明のカルシウム拮抗剤に用いられる有効成分は、その多くが従来から主に香料として使用されている化合物であるため、飲食品に添加することができる。例えば、乳飲料、清涼飲料、嗜好飲料、アルコール飲料などの飲料、チョコレート、キャンディ、錠菓、ガム、スナック菓子、クッキー、ケーキ、その他焼き菓子などの菓子類、氷菓、アイスクリームなどの冷菓類、即席麺類、レトルト食品、冷凍食品などの調理食品、調味料および栄養補助食品などの食品類に添加することにより、抗不整脈や抗脳血管攣縮など健康維持の機能を付加することができる。 Since many of the active ingredients used in the calcium antagonist of the present invention are compounds that have been conventionally used mainly as fragrances, they can be added to food and drink. For example, beverages such as milk beverages, soft drinks, taste beverages, alcoholic beverages, chocolate, candy, tablet confectionery, gum, snack confectionery, cookies, cakes, other confectionery such as baked confectionery, frozen confectionery such as ice confectionery and ice cream, instant By adding to cooked foods such as noodles, retort foods, frozen foods, and foods such as seasonings and nutritional supplements, health maintenance functions such as antiarrhythmia and anticerebral vasospasm can be added.
本発明のカルシウム拮抗剤を飲食品に添加する場合、添加量は０．００１〜５質量％であることが好ましい。 When adding the calcium antagonist of this invention to food-drinks, it is preferable that the addition amount is 0.001-5 mass%.
本発明カルシウム拮抗剤を飲食品に添加する方法は必要に応じて、乳化剤、分散剤および安定化剤などを加えることもできる。 In the method for adding the calcium antagonist of the present invention to foods and drinks, an emulsifier, a dispersant, a stabilizer and the like can be added as necessary.
本発明カルシウム拮抗剤を飲食品に添加する場合は、ビタミン、ミネラルおよびアミノ酸などの栄養強化剤、抗酸化剤、抗菌剤、食物繊維、血流促進剤および抗血栓剤など他の機能性成分を、本発明のカルシウム拮抗剤の機能を阻害しない範囲で併用することもできる。 When the calcium antagonist of the present invention is added to foods and drinks, other functional ingredients such as nutrient enhancers such as vitamins, minerals and amino acids, antioxidants, antibacterial agents, dietary fiber, blood flow promoters and antithrombotic agents are added. The calcium antagonist of the present invention can be used in combination as long as it does not inhibit the function.
本発明のカルシウム拮抗剤は、香水、化粧水、ファンデーション、口紅、クリーム、ローション、乳液、ジェル、パック、日焼け止めおよびサンオイルなどの化粧品類、石鹸、ボディーシャンプー、洗顔料などの身体洗浄剤、シャンプー、リンス、ヘアートリートメント剤、整髪料、染毛剤、パーマネント剤、養毛剤などの毛髪化粧料、シェービングフォーム、シェービングクリーム、アフターシェーブローション、歯磨き、洗口剤、粉末洗剤、液体洗剤、漂白剤、柔軟剤、浴剤、衛生用品および避妊具などの香粧品類に添加することができる。 Calcium antagonists of the present invention include perfumes, lotions, foundations, lipsticks, creams, lotions, emulsions, gels, packs, cosmetics such as sunscreens and sun oils, body cleansing agents such as soaps, body shampoos, face wash, Hair cosmetics such as shampoo, rinse, hair treatment, hair conditioner, hair dye, permanent agent, hair nourishing agent, shaving foam, shaving cream, after shave lotion, toothpaste, mouthwash, powder detergent, liquid detergent, bleach, softener It can be added to cosmetics such as preparations, bath preparations, hygiene products and contraceptives.
本発明カルシウム拮抗剤を香粧品類に添加する場合、添加量は、０．００１〜１５質量％であることが好ましい。 When adding this invention calcium antagonist to cosmetics, it is preferable that the addition amount is 0.001-15 mass%.
本発明のカルシウム拮抗剤を香粧品に添加する方法は特に限定されないが、必要に応じて乳化剤、分散剤、安定化剤および賦形剤などを加えることもできる。 The method for adding the calcium antagonist of the present invention to the cosmetic is not particularly limited, but emulsifiers, dispersants, stabilizers, excipients, and the like can be added as necessary.
本発明のカルシウム拮抗剤を香粧品に添加する場合は、抗酸化剤、ビタミン、ミネラル、アミノ酸、保湿剤、紫外線吸収剤、抗菌剤、抗かび剤、メラニン生成抑制剤、養毛剤、冷感剤、温感剤、吸収促進剤、血流促進剤および抗血栓剤など他の機能性物質を、本発明のカルシウム拮抗剤の機能を阻害しない範囲で併用することもできる。 When adding the calcium antagonist of the present invention to cosmetics, antioxidants, vitamins, minerals, amino acids, moisturizers, ultraviolet absorbers, antibacterial agents, antifungal agents, melanin production inhibitors, hair nourishing agents, cooling sensates, Other functional substances such as warming agents, absorption promoters, blood flow promoters and antithrombotic agents can be used in combination as long as the functions of the calcium antagonist of the present invention are not inhibited.
（試験方法）
本発明におけるカルシウム拮抗作用の試験としては、カルシウムイオノフォア（Ａ２３１８７）を惹起剤とする血小板凝集抑制試験を採用した。カルシウムイオノフォアは、細胞内にカルシウムイオンを流入させる物質であり、多血小板血漿（以下、ＰＲＰという。）に加えた場合は血小板の凝集を惹起する。すなわち、ＰＲＰに被検物質を加え、カルシウムイオノフォア（Ａ２３１８７）を添加したときに血小板の凝集が阻害されれば、その被検物質試料はカルシウム拮抗作用を有するといえる。
(Test method)
As a test for calcium antagonism in the present invention, a platelet aggregation inhibition test using calcium ionophore (A23187) as an initiator was employed. Calcium ionophore is a substance that allows calcium ions to flow into cells, and causes platelet aggregation when added to platelet-rich plasma (hereinafter referred to as PRP). That is, if a test substance is added to PRP and calcium ionophore (A23187) is added, if the platelet aggregation is inhibited, it can be said that the test substance sample has a calcium antagonistic action.
具体的には、人の血液に１０％濃度になるように３．８％クエン酸ナトリウム液を加え、この血液を１０００ｒｐｍで１０分間遠心分離し、上層部を採取、これをＰＲＰとした。更に下層部を３０００ｒｐｍで１５分間遠心分離し、上層部から乏血小板血漿（以下、ＰＰＰという。）を採取して、これを血小板凝集能測定時におけるコントロールとした。 Specifically, 3.8% sodium citrate solution was added to human blood to a concentration of 10%, this blood was centrifuged at 1000 rpm for 10 minutes, and the upper layer portion was collected and used as PRP. Further, the lower layer was centrifuged at 3000 rpm for 15 minutes, and platelet poor plasma (hereinafter referred to as PPP) was collected from the upper layer and used as a control at the time of measuring the platelet aggregation ability.
測定装置として、興和株式会社製の血小板凝集能測定装置（コーワＰＡ−２０）を使用し、被験物質を加えず、カルシウムイオノフォア（Ａ２３１８７）のみを加えた対象凝集曲線に対する最大凝集率を１００％としたときの各試料濃度段階の最大凝集率を求めた。 As a measuring device, a platelet aggregation measuring device (Kowa PA-20) manufactured by Kowa Co., Ltd. was used, and the maximum aggregation rate with respect to the target aggregation curve without adding the test substance and adding only the calcium ionophore (A23187) was 100%. The maximum aggregation rate at each sample concentration step was determined.
被験物質を測定容器に入れ、さらにＰＲＰ２７０μｌを加えたものを測定装置に設置し、３７℃の温度で撹拌しながら３０秒間インキュベートした。続いて、３０秒以内に凝集惹起剤として上記ＰＲＰ中の濃度が１５μＭになるように調整したカルシウムイオノフォア（Ａ２３１８７）のメタノール溶液を加え、測定容器設置から７分後までの凝集率を測定した。試験試料が１ｍＭで５０％以上の阻害活性を示した場合は、順次濃度を半分に落として活性を測定した。カルシウムイオノフォアは、細胞内にカルシウムイオンを流入させる物質である。カルシウムイオノフォアをＰＲＰに加えた場合は、血小板の凝集を惹起する。 A test substance was placed in a measurement container, and further 270 μl of PRP was added to the measurement apparatus, and incubated at 37 ° C. with stirring for 30 seconds. Subsequently, a methanol solution of calcium ionophore (A23187) adjusted so that the concentration in the PRP was 15 μM was added as an agglutination-inducing agent within 30 seconds, and the agglomeration rate was measured after 7 minutes from the installation of the measurement container. When the test sample showed an inhibitory activity of 50% or more at 1 mM, the activity was measured by successively reducing the concentration by half. A calcium ionophore is a substance that allows calcium ions to flow into cells. When calcium ionophore is added to PRP, it causes platelet aggregation.
カルシウムイオノフォア（Ａ２３１８７）による血小板凝集阻害活性は、次の計算方法により血小板凝集阻害率を求めることで評価した。 Platelet aggregation inhibitory activity by calcium ionophore (A23187) was evaluated by determining the platelet aggregation inhibition rate by the following calculation method.
（血小板凝集阻害率計算法）
・ＰＲＰ＋Ａ２３１８７のみを加えたときの最大凝集率をＡとする。
・被験物質＋ＰＲＰ＋Ａ２３１８７を加えたときの最大凝集率をＢとする。
・凝集阻害率（％）をＣとすると
Ｃ＝１００−Ｂ／Ａ×１００。
(Platelet aggregation inhibition rate calculation method)
A is the maximum aggregation rate when only PRP + A23187 is added.
-Let B be the maximum aggregation rate when test substance + PRP + A23187 is added.
-When the aggregation inhibition rate (%) is C, C = 100−B / A × 100.
（試験結果）
前記試験方法において、被験物質の濃度が１ｍＭから開始して、順次、阻害活性が消失するまで試料を１／２希釈して添加し、血小板凝集阻害活性を測定した。その試験結果を表１に示す。
(Test results)
In the test method, the concentration of the test substance was started at 1 mM, and the sample was sequentially diluted by 1/2 until the inhibitory activity disappeared, and the platelet aggregation inhibitory activity was measured. The test results are shown in Table 1.
表１に示すように、本発明の化合物には、３０μＭ以下の低濃度においても強い阻害活性が確認された。 As shown in Table 1, the compound of the present invention was confirmed to have a strong inhibitory activity even at a low concentration of 30 μM or less.
以下に、本発明のカルシウム拮抗剤の製剤例について、一例を示す。 Below, an example is shown about the formulation example of the calcium antagonist of this invention.
・錠剤配合例（配合割合は質量比である。）
──────────────────────
本発明のカルシウム拮抗剤 ５．０
６％ＨＰＣ乳糖 ８０．０
ステアリン酸マグネシウム ４．０
バレイショデンプン ６．０
──────────────────────
・軟膏剤配合例（配合割合は質量比である。）
─────────────────────────
白色ワセリン ２０．０
ステアリルアルコール ２２．０
プロピレングリコール １２．０
ラウリル硫酸ナトリウム １．５
パラベン ０．２
本発明のカルシウム拮抗剤 ５．０
精製水 ３９．３
─────────────────────────
・入浴剤配合例（配合割合は質量比である。）
――――――――――――――――――――――─
炭酸水素ナトリウム ５０．０
硫酸ナトリウム ４５．０
本発明のカルシウム拮抗剤 １．３
香料 ０．７
色素 ３．０
───────────────────────
以下に、本発明のカルシウム拮抗剤のうち、血小板凝集抑制剤の食品への配合例について一例を示す。
・ Tablet blending example (blending ratio is mass ratio)
──────────────────────
Calcium antagonist of the present invention 5.0
6% HPC lactose 80.0
Magnesium stearate 4.0
Potato starch 6.0
──────────────────────
-Ointment formulation example (mixing ratio is mass ratio)
─────────────────────────
White petrolatum 20.0
Stearyl alcohol 22.0
Propylene glycol 12.0
Sodium lauryl sulfate 1.5
Paraben 0.2
Calcium antagonist of the present invention 5.0
Purified water 39.3
─────────────────────────
・ Bath bath formulation example (mixing ratio is mass ratio)
――――――――――――――――――――――――
Sodium bicarbonate 50.0
Sodium sulfate 45.0
Calcium antagonist of the present invention 1.3
Fragrance 0.7
Dye 3.0
───────────────────────
Below, an example is shown about the compounding example to the foodstuff of a platelet aggregation inhibitor among the calcium antagonists of this invention.
・アイスクリーム配合例（配合割合は質量比である。）
────────────────────────
全脂練乳 １０．０
生クリーム ９．４
無塩バター ２．０
脱脂粉乳 ３．４
砂糖 １２．０
安定剤 ０．３
乳化剤 ０．２
ｐＨ調整剤 ０．１
カラメル色素 ０．１
本発明のカルシウム拮抗剤 ０．０１
香料 ０．０１
水 ４９．０
────────────────────────
・クッキー生地配合例（配合割合は質量比である。）
────────────────────────
薄力粉 ６２．５
全粒粉 ３７．５
ショートニング ３０．０
全卵 ３０．０
砂糖 ２０．０
水飴 １．０
脱脂粉乳 ５．０
食塩 １．２
食用油脂 ３０．０
重炭酸ソーダ １．０
重炭酸アンモニウム １．０
本発明のカルシウム拮抗剤 ０．１
香料 ０．３
水 １１．０
────────────────────────
・チョコレート配合例（配合割合は質量比である。）
─────────────────────────
カカオ液 １２．０
カカオバター ２４．０
ショ糖 ３３．０
フルクリームミルクパウダー １９．０
スキムミルクパウダー １１．４
レシチン ０．５
本発明のカルシウム拮抗剤 ０．０１
香料 ０．１
─────────────────────────
・ノンオイルドレッシング配合例（配合割合は質量比である。）
─────────────────────────
濃口醤油 １０．０
醸造酢 ６．０
リンゴ酢 ５．０
レモン果汁 ４．０
液糖 ７．０
食塩 ２．０
調味料 ７．０
香料 ０．２
本発明のカルシウム拮抗剤 ０．０１
水 ５０．０
─────────────────────────
・飲料配合例（配合割合は質量比である。）
――――――――――――――――――――――───
果糖ぶどう糖液糖 ６０．０
アップル透明果汁 ４．３
クエン酸 ２．３
クエン酸三ナトリウム ０．８
アスコルビン酸 ０．２
スクラロース ０．０３
アセスルファムカリウム ０．０２
香料 ０．９９
本発明のカルシウム拮抗剤 ０．１
水 ３１．０
――――――――――――――――――――――───
・チューインガム配合例（配合割合は質量比である。）
――――――――――――――――――――――─
ガムベース ２０．０
砂糖 ６０．０
ブドウ糖 １０．０
水飴 ８．０
グリセリン ５．０
香料 ０．９
本発明のカルシウム拮抗剤 ０．１
───────────────────────
-Ice cream formulation example (mixing ratio is mass ratio)
────────────────────────
Whole fat condensed milk 10.0
Fresh cream 9.4
Unsalted butter 2.0
Nonfat dry milk 3.4
Sugar 12.0
Stabilizer 0.3
Emulsifier 0.2
pH adjuster 0.1
Caramel pigment 0.1
Calcium antagonist of the present invention 0.01
Fragrance 0.01
Water 49.0
────────────────────────
・ Cookie dough formulation example (mixing ratio is mass ratio)
────────────────────────
Soft flour 62.5
Whole grain 37.5
Shortening 30.0
Whole egg 30.0
Sugar 20.0
Minamata 1.0
Nonfat dry milk 5.0
Salt 1.2
Edible oils and fats 30.0
Sodium bicarbonate 1.0
Ammonium bicarbonate 1.0
Calcium antagonist of the present invention 0.1
Fragrance 0.3
Water 11.0
────────────────────────
・ Chocolate blending example (mixing ratio is mass ratio)
─────────────────────────
Cocoa liquor 12.0
Cocoa butter 24.0
Sucrose 33.0
Full cream milk powder 19.0
Skim milk powder 11.4
Lecithin 0.5
Calcium antagonist of the present invention 0.01
Fragrance 0.1
─────────────────────────
-Non-oil dressing formulation example (mixing ratio is mass ratio)
─────────────────────────
Dark soy sauce 10.0
Brewing vinegar 6.0
Apple cider vinegar 5.0
Lemon juice 4.0
Liquid sugar 7.0
Salt 2.0
Seasoning 7.0
Fragrance 0.2
Calcium antagonist of the present invention 0.01
Water 50.0
─────────────────────────
・ Beverage formulation example (mixing ratio is mass ratio)
―――――――――――――――――――――――― ──
Fructose glucose liquid sugar 60.0
Apple transparent fruit juice 4.3
Citric acid 2.3
Trisodium citrate 0.8
Ascorbic acid 0.2
Sucralose 0.03
Acesulfame potassium 0.02
Perfume 0.99
Calcium antagonist of the present invention 0.1
Water 31.0
―――――――――――――――――――――――― ──
-Chewing gum blending example (blending ratio is mass ratio)
――――――――――――――――――――――――
Gum base 20.0
Sugar 60.0
Glucose 10.0
Minamata 8.0
Glycerin 5.0
Fragrance 0.9
Calcium antagonist of the present invention 0.1
───────────────────────
本発明のカルシウム拮抗剤は、香料として使用実績がある化合物であり、刺激性などは極めて小さく、飲食品や香粧品類、医薬品など幅広く添加することができる。また、本発明の化合物群は、容易に合成ができるため大量生産が可能である。 The calcium antagonist of the present invention is a compound that has been used as a fragrance, has very little irritation, and can be widely added to foods, beverages, cosmetics, pharmaceuticals, and the like. Further, the compound group of the present invention can be synthesized easily and can be mass-produced.
Claims (7)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2007260673A JP5224235B2 (en) | 2007-10-04 | 2007-10-04 | Calcium antagonist |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2007260673A JP5224235B2 (en) | 2007-10-04 | 2007-10-04 | Calcium antagonist |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013006121A Division JP5626609B2 (en) | 2013-01-17 | 2013-01-17 | Calcium antagonist |
| JP2013006120A Division JP2013075914A (en) | 2013-01-17 | 2013-01-17 | Calcium antagonist |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009091262A true JP2009091262A (en) | 2009-04-30 |
| JP5224235B2 JP5224235B2 (en) | 2013-07-03 |
Family
ID=40663599
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007260673A Expired - Fee Related JP5224235B2 (en) | 2007-10-04 | 2007-10-04 | Calcium antagonist |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP5224235B2 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011256121A (en) * | 2010-06-07 | 2011-12-22 | Kao Corp | Potential-dependent cation channel inhibitor |
| WO2013146539A1 (en) * | 2012-03-27 | 2013-10-03 | 辻本化学工業株式会社 | Ppars agonist activity enhancing drug |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63255222A (en) * | 1987-04-14 | 1988-10-21 | Nippon Petrochem Co Ltd | Calcium antagonistic agent for remedy of ischemic cardiopathy composed of coumarins |
| JPH09124476A (en) * | 1995-11-06 | 1997-05-13 | Pola Chem Ind Inc | Calcium antagonistic agent |
| JP2001240528A (en) * | 2000-02-29 | 2001-09-04 | Soda Aromatic Co Ltd | Tyrosinase activity inhibitor |
| JP2004323476A (en) * | 2003-04-28 | 2004-11-18 | Soda Aromatic Co Ltd | Antimycotic agent and antimicrobial product produced by using the same |
| JP2005035929A (en) * | 2003-07-15 | 2005-02-10 | Soda Aromatic Co Ltd | Antimicrobial agent and antimicrobial product using the same |
-
2007
- 2007-10-04 JP JP2007260673A patent/JP5224235B2/en not_active Expired - Fee Related
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63255222A (en) * | 1987-04-14 | 1988-10-21 | Nippon Petrochem Co Ltd | Calcium antagonistic agent for remedy of ischemic cardiopathy composed of coumarins |
| JPH09124476A (en) * | 1995-11-06 | 1997-05-13 | Pola Chem Ind Inc | Calcium antagonistic agent |
| JP2001240528A (en) * | 2000-02-29 | 2001-09-04 | Soda Aromatic Co Ltd | Tyrosinase activity inhibitor |
| JP2004323476A (en) * | 2003-04-28 | 2004-11-18 | Soda Aromatic Co Ltd | Antimycotic agent and antimicrobial product produced by using the same |
| JP2005035929A (en) * | 2003-07-15 | 2005-02-10 | Soda Aromatic Co Ltd | Antimicrobial agent and antimicrobial product using the same |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011256121A (en) * | 2010-06-07 | 2011-12-22 | Kao Corp | Potential-dependent cation channel inhibitor |
| WO2013146539A1 (en) * | 2012-03-27 | 2013-10-03 | 辻本化学工業株式会社 | Ppars agonist activity enhancing drug |
| JP5469781B1 (en) * | 2012-03-27 | 2014-04-16 | 辻本化学工業株式会社 | PPARs agonist activity enhancer |
| US9999612B2 (en) | 2012-03-27 | 2018-06-19 | Tsujimoto Chemical Co., Ltd. | PPARs agonist activity enhancing drug |
Also Published As
| Publication number | Publication date |
|---|---|
| JP5224235B2 (en) | 2013-07-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4887499B2 (en) | Active oxygen scavenger and moisturizer containing wild watermelon extract | |
| JP2010053122A (en) | Lipid synthesis inhibitor | |
| JP5224234B2 (en) | Platelet aggregation inhibitor | |
| JP5224235B2 (en) | Calcium antagonist | |
| JP5305419B2 (en) | Platelet aggregation inhibitor | |
| US20160022556A1 (en) | 1,5-anhydro-d-glucitol-containing collagen production accelerator | |
| JP5626609B2 (en) | Calcium antagonist | |
| JP6456032B2 (en) | Sirt1 activator and use of the Sirt1 activator | |
| JP4657778B2 (en) | Arachidonic acid metabolism inhibitor | |
| JP4953627B2 (en) | Arachidonic acid metabolism inhibitor | |
| JP4906282B2 (en) | Melanin production inhibitor | |
| JP5536913B2 (en) | Platelet aggregation inhibitor | |
| JP7179025B2 (en) | Anti-inflammatory composition containing novel kaempferol compounds derived from post-fermented tea | |
| JP5527736B2 (en) | Platelet aggregation inhibitor | |
| JP2008013486A (en) | Arachidonate metabolism inhibitor | |
| JP7030692B2 (en) | Moisturizing composition containing 3-O-galloyl-3,3', 5,5', 7-pentahydroxyflavon | |
| JP2013075914A (en) | Calcium antagonist | |
| JP2013082738A (en) | Platelet aggregation inhibitor | |
| JP4988166B2 (en) | Xanthine oxidase inhibitor | |
| JP5536912B2 (en) | Platelet aggregation inhibitor | |
| JP5507892B2 (en) | Active oxygen-induced disorder inhibitor | |
| JP2013082739A (en) | Platelet aggregation inhibitor | |
| JP7121758B2 (en) | Whitening composition containing novel kaempferol compound derived from post-fermented tea | |
| JP6753662B2 (en) | Anti-glycation agent | |
| JP2024041535A (en) | SIRT1 activator |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20100226 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20100226 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100819 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20121120 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20121225 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20121225 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130117 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130226 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130304 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5224235 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20160322 Year of fee payment: 3 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |